Anti-PTEN (C-Term), clone Y184 (rabbit monoclonal)

Species Reactivity	Key Applications	Host	Format	Antibody Type
H, M, R	ICC, IHC, IP, WB	M	Purified	Monoclonal Antibody

Species Reactivity

Key Applications

Host

Format

Antibody Type

H, M, R

ICC, IHC, IP, WB

Purified

Monoclonal Antibody

Description
Catalogue Number	MAB4037
Replaces	04-409
Brand Family	Chemicon®
Trade Name	Chemicon
Description	Anti-PTEN Antibody, CT, clone A2b1
Alternate Names	MMAC1 TEP1

Description

Catalogue Number

MAB4037

Replaces

04-409

Brand Family

Chemicon®

Trade Name

Chemicon

Description

Anti-PTEN Antibody, CT, clone A2b1

Alternate Names

MMAC1
TEP1

Product Information
Format	Purified
Control	Breast tumor tissue Purified active kinase is Catalogue Number 14-488
Presentation	Protein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.

Product Information

Format

Purified

Control

Breast tumor tissue
Purified active kinase is Catalogue Number 14-488

Presentation

Protein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.

Applications
Application	Anti-PTEN Antibody, C-terminus, clone A2b1 is an antibody against PTEN for use in IC, IH, IP & WB.
Key Applications	Immunocytochemistry Immunohistochemistry Immunoprecipitation Western Blotting
Applications Not Recommended	Immunohistochemistry (Paraffin)
Application Notes	Western blot 1:100 (55 kDa) Immunocytochemistry Immunohistochemistry: 1:20 to 1:50 for acetone-fixed, fresh frozen tissue. Not effective for paraffin sections. Immunoprecipitation 1:10 to 1:20 Protocol for immunohistochemistry of frozen tissue sections on glass slides. 1. Fix sections for 5 minutes with cold acetone. 2. Air dry 3. Wash sections with PBS 4. Add blocking solution (horse serum) for 20 minutes 5. Add diluted PTEN antibody and incubate for 1 hour at room temperature. 6. Wash with PBS 7. Add biotinylated secondary antibody (horse anti-mouse, or equivalent). 8. Incubate for 30 minutes at room temperature. 9. Wash with PBS 10. Detect with ABC (Avidin-Peroxidase-Complex) or equivalent. 11. Wash with PBS 12. Develop with DAB substrate. 13. Hematoxylin dye may be used as a counterstain for visualizing nuclei.Breast tumor tissue gives good staining. Prostate tissue does not stain.Optimal working dilutions must be determined by end user.

Applications

Application

Anti-PTEN Antibody, C-terminus, clone A2b1 is an antibody against PTEN for use in IC, IH, IP & WB.

Key Applications

Immunocytochemistry
Immunohistochemistry
Immunoprecipitation
Western Blotting

Applications Not Recommended

Immunohistochemistry (Paraffin)

Application Notes

Western blot 1:100 (55 kDa)

Immunocytochemistry

Immunohistochemistry: 1:20 to 1:50 for acetone-fixed, fresh frozen tissue. Not effective for paraffin sections.

Immunoprecipitation 1:10 to 1:20

Protocol for immunohistochemistry of frozen tissue sections on glass slides.

1. Fix sections for 5 minutes with cold acetone.

2. Air dry

3. Wash sections with PBS

4. Add blocking solution (horse serum) for 20 minutes

5. Add diluted PTEN antibody and incubate for 1 hour at room temperature.

6. Wash with PBS

7. Add biotinylated secondary antibody (horse anti-mouse, or equivalent).

8. Incubate for 30 minutes at room temperature.

9. Wash with PBS

10. Detect with ABC (Avidin-Peroxidase-Complex) or equivalent.

11. Wash with PBS

12. Develop with DAB substrate.

13. Hematoxylin dye may be used as a counterstain for visualizing nuclei.Breast tumor tissue gives good staining. Prostate tissue does not stain.Optimal working dilutions must be determined by end user.

Biological Information
Immunogen	Anti-PTEN was generated by immunization with a 10 amino acid peptide corresponding to amino acids 387-400 near the C-terminus of human PTEN.
Epitope	C-terminus
Clone	A2b1
Concentration	Please refer to the Certificate of Analysis for the lot-specific concentration.
Host	Mouse
Specificity	Specifically recognizes PTEN, a tumor suppressor protein located on human chromosome 10 (Steck, '97; Li, '97; Rhei, '97) that is often mutated in various types of advanced cancers (Rhei, '97). The PTEN protein exhibits protein phosphatase activity (Myers, '97) and can suppress the growth of glioma cells (Furnari, '97). The antibody recognizes human and mouse PTEN and is specific for the C-terminus. Other species not tested. Reactivity with human fibroblasts, breast epithelial and lung cancer cell lines has been confirmed by western blot, and antibody specificity has been confirmed by peptide blocking studies. PTEN is covered under U.S. patents 6,262,242, 6,482,795 and U.S. patent application 10/299,003.
Isotype	IgG1
Species Reactivity	Human Mouse Rat
Antibody Type	Monoclonal Antibody
Entrez Gene Number	NM_000314.4
Entrez Gene Summary	This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.
Gene Symbol	PTEN MMAC1 MHAM TEP1 BZS PTEN1 MGC11227 EC 3.1.3.67 EC 3.1.3.16 EC 3.1.3.48
Purification Method	Protein A Purfied
UniProt Number	P60484
UniProt Summary	FUNCTION: SwissProt: P60484 # Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. COFACTOR: Magnesium. SIZE: 403 amino acids; 47166 Da SUBUNIT: Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. SUBCELLULAR LOCATION: Cytoplasm. TISSUE SPECIFICITY: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas. DOMAIN: SwissProt: P60484 The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function. PTM: Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit and promote PDZ-binding. DISEASE: SwissProt: P60484 # Mutations of PTEN are found in a large number of cancers. & Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD. & Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes. & Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis. & Defects in PTEN are a cause of squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]. & Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089]. & Defects in PTEN are a cause of Proteus syndrome [MIM:176920]. Proteus syndrome is a hamartomatous disorder characterized by overgrowth of multiple tissues, connective tissue and epidermal naevi, and vascular malformations. These presentations are usually apparent at birth or soon after and continue to develop as the patient ages. It is named after the Greek god Proteus who, legend has it, could change his shape at will to avoid capture. Tumors, mostly benign but some malignant, have also been reported in Proteus syndrome, generally presenting by the age of 20 years and including papillary adenocarcinoma of the testis, meningioma, and cystadenoma of the ovaries. & Defects in PTEN are a cause of oligodendroglioma [MIM:137800]; also called oligodendroblastoma or familial glioma of brain. Oligodendroglioma is a usually benign neoplasm derived from and composed of oligodendrogliocytes in varying stages of differentiation. The majority are seen in adults in the white matter of the brain. & Defects in PTEN are a cause of VACTERL association with hydrocephalus [MIM:276950]; which includes also VATER association with hydrocephalus. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. & Defects in PTEN are involved in prostate cancer [MIM:176807]. & Defects in PTEN are a cause of macrocephaly/autism syndrome [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). SIMILARITY: Contains 1 C2 tensin-type domain. & Contains 1 phosphatase tensin-type domain.
Molecular Weight	55 kDa

Biological Information

Immunogen

Anti-PTEN was generated by immunization with a 10 amino acid peptide corresponding to amino acids 387-400 near the C-terminus of human PTEN.

Epitope

C-terminus

Clone

A2b1

Concentration

Please refer to the Certificate of Analysis for the lot-specific concentration.

Host

Mouse

Specificity

Specifically recognizes PTEN*, a tumor suppressor protein located on human chromosome 10 (Steck, '97; Li, '97; Rhei, '97) that is often mutated in various types of advanced cancers (Rhei, '97). The PTEN protein exhibits protein phosphatase activity (Myers, '97) and can suppress the growth of glioma cells (Furnari, '97). The antibody recognizes human and mouse PTEN and is specific for the C-terminus. Other species not tested. Reactivity with human fibroblasts, breast epithelial and lung cancer cell lines has been confirmed by western blot, and antibody specificity has been confirmed by peptide blocking studies.

*PTEN is covered under U.S. patents 6,262,242, 6,482,795 and U.S. patent application 10/299,003.

Isotype

IgG1

Species Reactivity

Human
Mouse
Rat

Antibody Type

Monoclonal Antibody

Entrez Gene Number

NM_000314.4

Entrez Gene Summary

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.

Gene Symbol

PTEN
MMAC1
MHAM
TEP1
BZS
PTEN1
MGC11227
EC 3.1.3.67
EC 3.1.3.16
EC 3.1.3.48

Purification Method

Protein A Purfied

UniProt Number

P60484

UniProt Summary

FUNCTION: SwissProt: P60484 # Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.

COFACTOR: Magnesium.

SIZE: 403 amino acids; 47166 Da

SUBUNIT: Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro.

SUBCELLULAR LOCATION: Cytoplasm.

TISSUE SPECIFICITY: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.

DOMAIN: SwissProt: P60484 The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.

PTM: Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit and promote PDZ-binding.

DISEASE: SwissProt: P60484 # Mutations of PTEN are found in a large number of cancers. & Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD. & Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes. & Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis. & Defects in PTEN are a cause of squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]. & Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089]. & Defects in PTEN are a cause of Proteus syndrome [MIM:176920]. Proteus syndrome is a hamartomatous disorder characterized by overgrowth of multiple tissues, connective tissue and epidermal naevi, and vascular malformations. These presentations are usually apparent at birth or soon after and continue to develop as the patient ages. It is named after the Greek god Proteus who, legend has it, could change his shape at will to avoid capture. Tumors, mostly benign but some malignant, have also been reported in Proteus syndrome, generally presenting by the age of 20 years and including papillary adenocarcinoma of the testis, meningioma, and cystadenoma of the ovaries. & Defects in PTEN are a cause of oligodendroglioma [MIM:137800]; also called oligodendroblastoma or familial glioma of brain. Oligodendroglioma is a usually benign neoplasm derived from and composed of oligodendrogliocytes in varying stages of differentiation. The majority are seen in adults in the white matter of the brain. & Defects in PTEN are a cause of VACTERL association with hydrocephalus [MIM:276950]; which includes also VATER association with hydrocephalus. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. & Defects in PTEN are involved in prostate cancer [MIM:176807]. & Defects in PTEN are a cause of macrocephaly/autism syndrome [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).

SIMILARITY: Contains 1 C2 tensin-type domain. & Contains 1 phosphatase tensin-type domain.

Molecular Weight

55 kDa

Product Usage Statements
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Storage and Shipping Information

Storage Conditions

Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Packaging Information
Material Size	100 µg

Packaging Information

Material Size

100 µg

实验耗材

分子生物学试剂

蛋白与免疫学

生化试剂

细胞及检测试剂

色谱及层析

仪器设备

实验服务

办公用品

Anti-PTEN (C-Term), clone Y184 (rabbit monoclonal)

浏览了该商品的用户最终购买

浏览了该商品的用户还浏览了

特卖

重要规格表

我要咨询